No Carolina / NY / Florida
Ph: 561.316.3330

Kromek’s Digital Detectors Used in World’s 1st Digital SPECT/CT Scanner for Higher Energy Imaging

Detectors provide Spectrum Dynamics Medical’s digital SPECT/CT scanner with higher sensitivity and throughput

Summation

  • KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, is pleased to announce that one of its key customers, Spectrum Dynamics Medical, has introduced the world's first digital SPECT/CT scanner for higher energy imaging, using Kromek's digital detectors.
  • The increased sensitivity, improved energy resolution, and broader energy range of Kromek’s detector technology make it the right choice for the 400 Series and the advanced imaging and quantitative accuracy clinical users ask for.
  • Spectrum Dynamics has long been at the forefront of developing next-generation SPECT/CT scanners to deliver better patient outcomes, and we are pleased to be part of this significant advance in nuclear medical imaging technology.

Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, is pleased to announce that one of its key customers, Spectrum Dynamics Medical, has introduced the world’s first digital SPECT/CT scanner for higher energy imaging, using Kromek’s digital detectors.

Based on Spectrum Dynamics’ digital SPECT/CT platform, VERITON-CT 400 Series’ detector technology provides the benefits of increased sensitivity and throughput for Nuclear Medicine clinical applications using up to 400keV high-energy isotopes.

CZT is transforming the detector technology used in medical imaging leading to shorter scan times, lower radiation dose to the patient, and improved image quality and quantitative accuracy.

Kromek’s high-performance digital detectors, combined with Spectrum’s 360-degree, wide-bore SPECT/CT scanner and its advanced image reconstruction algorithms, increase the energy range up to 400 keV to support the throughput demand of current and new emerging nuclear medicine clinical applications.

The 400 Series digital detector technology sets new standards with a 2-4 times improvement in energy range, system sensitivity, and energy resolution. These improvements will significantly shorten the scan times associated with current analog or state-of-the-art digital technology.

Arnab Basu, CEO of Kromek Group, said: “We are delighted that our CZT detectors have been integrated into Spectrum Dynamics’ VERITON-CT 400 SPECT/CT systems. This enables enhanced image quality and breakthrough clinical capabilities in digital SPECT/CT. Spectrum Dynamics has long been at the forefront of developing next-generation SPECT/CT scanners to deliver better patient outcomes, and we are pleased to be part of this significant advance in nuclear medical imaging technology.”

Gilad Yoeli, CEO of Spectrum Dynamics, added: “Clinical users across the world provide us with feedback on the Nuclear Medicine challenges they face. Providing the technology to address such challenges is what drives us. The increased sensitivity, improved energy resolution, and broader energy range of Kromek’s detector technology make it the right choice for the 400 Series and the advanced imaging and quantitative accuracy clinical users ask for.”

More News

Gyros Protein Technologies Introduces Gyrolab Generic Rodent ADA Kit Reagents to Support Preclinical Immunogenicity Assessment

The new Roden ADA Kit expedites bioanalysis by removing the need for assay development and optimization across molecules to provide robust, reproducible, reliable data from nanoliter sample volumes. This is beneficial when ADA assessment is evaluated in preclinical animal models where sample volume may be limited.

Unleashing Biotech Potential: ATLATL Scientific & Miltenyi Biotec Partnership

Since the inception of their partnership five years ago, ATLATL Scientific and Miltenyi Biotec have worked closely together to leverage their respective expertise and resources.

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy